Risultati per: Test delle urine per la diagnosi di cancro

Illustrato Bilancio sociale. Parte secondo lotto della Biobanca

Illustrato Bilancio sociale. Parte secondo lotto della Biobanca

‘Positivo 30 mila nuove assunzioni tra medici e infermieri’

Ma graduatoria dopo il primo semestre sulla base dell’esito degli esami

Non solo un problema dei bimbi ma “attenzione all’autodiagnosi”

Low follow-up rates suggest missed opportunities to identify patients with clinically important proteinuria.

Introduction
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) with a relapsing-remitting nature. With adequate non-invasive prediction of mucosal inflammation, endoscopies can be prevented and treatment optimised earlier for better disease control. We aim to validate and recalibrate commonly used patient-reported symptom scores combined with a faecal calprotectin (FC) home test as non-invasive diagnostic tool for remote monitoring of IBD, both in daily practice and in a strict trial setting. Endoscopy will be used as the gold standard.

Methods and analysis
In this multicentre prospective validation study, adult IBD patients are asked to fill out questionnaires regarding disease activity (Monitor IBD At Home, mobile Health Index, Manitoba IBD Index, IBD control and patient-HBI/patient-Simple Clinical Colitis Activity Index), perform a FC home test and collect a stool sample for routine laboratory FC measurement, before the start of the bowel preparation for the ileocolonoscopy. Endoscopic disease activity will be scored according to the simplified endoscopic score for Crohn’s disease (CD) for CD patients or Ulcerative Colitis Endoscopic Index for Severity and Mayo Endoscopic Subscore for ulcerative colitis patients. The main study outcome is the diagnostic test accuracy of the various patient-reported scores to assess mucosal inflammation in combination with a FC home test.

Ethics and dissemination
This study is approved by the Medical Research Ethics Committee of azM/UM in Maastricht dated 03 March 2021 (METC 20–085) and is monitored by the Clinical Trial Centre Maastricht according to Good Clinical Practice guidelines. Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals.

Trial registration number
NCT05886322

The US Food and Drug Administration (FDA) approved the first at-home test for syphilis for sale without a prescription. The test, manufactured by NOWDiagnostic and called First To Know Syphilis Test, arrives amid an 80% increase in cases in the US between 2018 and 2022, from 115 000 to 207 000 cases.

Allergologi, ‘falsi allergici’ costretti a farmaci meno efficaci

Accuratezza pari o maggiore dei calcolatori in uso

Annals of Internal Medicine, Ahead of Print.

Annals of Internal Medicine, Ahead of Print.

Per l’86% degli oncologi sono troppe le disparità di accesso alle cure

Per 86% oncologi sono troppe le disparità di accesso alle cure

Visita all’Istituto di oncologia molecolare di Fondazione Airc